

Medicaid Fee- for- Service Providers Dispense Brand Name Drug when Less Expensive than Generic Program

Effective immediately, Pepcid suspension will be removed from the program due to availability issues.

Effective December 18, 2014, the following changes will be made to the Dispense Brand Name Drug when Less Expensive than Generic Program:

- Cellcept suspension, Focalin XR 5mg, Rapamune tablet and Xeloda will be added to the Program.
- Niaspan and Wellbutrin XL will be removed from the Program.

In conformance with State Education Law which intends that patients receive the lower cost alternative, brand name drugs included in this program:

- Do not require 'Dispense as Written' (DAW) or 'Brand Medically Necessary' on the prescription.
- Have a generic copayment.
- Are paid at the Brand Name Drug reimbursement rate or usual and customary price, whichever is lower (SMAC/FUL are not applied).
- Do not require a new prescription if the drug is removed from this program.

IMPORTANT BILLING INFORMATION

Prescription claims submitted to the Medicaid program **do not require** the submission of Dispense as Written/Product Selection Code of '1'; **Pharmacies can submit any valid NCPDP field (408-D8) value.**

List of Brand Name Drugs included in this program* (Updated 12/01/14):

Accolate	Diastat	Patanase
Adderall XR	Diovan HCT	Pulmicort Respules
Alphagan P 0.15%	Epivir HBV	Rapamune tablet
Aldara	Exforge	Soriatane
Astepro	Felbatol	Symbyax
Bactroban cream	Focalin XR (5mg,15mg,30mg,40mg)	Tegretol suspension
Baraclude	Gabitril 2mg & 4mg	TOBI
Carac	Hepsera	Toprol XL
Carbatrol	Kadian	Trileptal suspension
Catapres-TTS	Lidoderm	Trizivir
Cellcept suspension	Mepron	Wellbutrin
Combivir	Myfortic	Xeloda
Depakote sprinkle	Ortho Evra	

*List is subject to change

Please keep in mind that drugs in this program may be subject to prior authorization requirements of other pharmacy programs, promoting the use of the most cost-effective product.